ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2156

Anti-Cyclic Citrullinated Protein Antibodies As a Predictor of Response to Tocilizumab in Patients with Rheumatoid arthritis   A Prospective Study

Kensuke Kume1, Kanzo Amano1, Susumu Yamada1, Kuniki Amano2, Kazuhiko Hatta3, Hiroyuki Ohta4 and Noriko Kuwaba5, 1Rheumatology, Hiroshima Clinic, Hiroshima, Japan, 2Rheumatology, Sky Clinic, Hiroshima, Japan, 3Rheumatology, Hatta Clinic, Kure, Japan, 4Medical Research, hiroshima clinic, Hiroshima, Japan, 5Medical Research, Sanki Clinical Link, Hiroshima, Japan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: anti-CCP antibodies, rheumatoid arthritis (RA) and tocilizumab

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy

Session Type: Abstract Submissions (ACR)

Background/Purpose:  Tocilizumab, interleukin-6 receptor antibody is very effective in patients with rheumatoid arthritis (RA). Anti-cyclic citrullinated protein antibodies (ACPA) are highly specific and sensitive for RA. There are several reports that the correlation between the efficacy of anti-tumor necrosis factor and the titer of ACPA. There is no evidence that the correlation between the efficacy of Tocilizumab and ACPA.To investigate the Tocilizumab on ACPA, and its association with treatment response.

Methods: RA patients were eligible if they had active disease despite treatment with methotrexate (MTX).  Fifty four consecutive IgM-rheumatoid factor positive patients with RA were treated with infusion of 8mg/kg tocilizumab every 4 weeks.Disease activity was assessed by DAS28 score. ACPA titer was measured by a commercial ELISA at Week 0 and Week 24.The primary outcome was correlation between clinical response to therapy and ACPA titer. Secondary outcome was the change of ACPA titer from baseline to week 24.

Results: Primary outcome: There was a significant correlation between clinical response to therapy and ACPA titer(r=0.54, p<0.02). Secondary outcome: There was no change of ACPA titer from baseline to week 24(p=0.76). No patient at baseline turned negative at week 24 for ACPA (negative cut off<4.5U/ml).

Conclusion: ACPA titer might be predictor of the efficacy of Tocilizumab in patients with RA. Tocilizumab treatment didn’t affect the change of ACPA titer.


Disclosure:

K. Kume,
None;

K. Amano,
None;

S. Yamada,
None;

K. Amano,
None;

K. Hatta,
None;

H. Ohta,
None;

N. Kuwaba,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-cyclic-citrullinated-protein-antibodies-as-a-predictor-of-response-to-tocilizumab-in-patients-with-rheumatoid-arthritis-a-prospective-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology